

Index

- A3 trial, 185–186
A4 trial, 179, 250, 338, 398, 401, 511
A45 trial, 185–186, 510
abeotaxane (TPI-287), 225
academic institutions/academics
 career progression, 497, 499–500, 501
 collaborations
 ACTC, 11, 182–187, 510
 ADCS, 177–178, 432–433
 ATRI, 178–182
 with pharmaceutical companies, 8, 39–41
 conflicts of interest, 432–433
 cultural shifts, 501
 drug discovery, 34–39
 hosting trial sites, 171, 175
 translational research, 437–438, 498–499
 SPARK program, 438–447
 training, 438, 442, 447, 484, 499
Accelerating Medicines Partnership®
 Program for Alzheimer's Disease (AMP® AD), 63, 507–508, 510–511
access to experimental drugs, 301–308
access to trials, 209, 252
acetylcholine (ACh), 26
 genes involved in metabolism, 405–408
acetylcholinesterase (AChE), 406
acetylcholinesterase (AChE) inhibitors
 donepezil, 408–412
 EEG changes, 423
 galantamine, 409, 412–413
 huperazine A, 411, 413
 pharmacogenomics, 404, 408–413
 phenserine, 55–56
 rivastigmine, 410, 413
 tacrine, 26, 74, 411
aciclovir, 56–57
ACTC *see* Alzheimer's Clinical Trial Consortium
Acti-v8 Your Brain program, 209
activities of daily living (ADL), 7, 234, 235, 336
 correlation between function and cognition, 285–286
 passive monitoring, 294
adaptive financing, 474
adaptive trial designs, 10–11, 16–17, 151, 236–237, 253
 adaptive randomization, 237
 FTLD trials, 227
ADAS-cog scale, 281, 282–283, 284–285, 455
ADCOMS score, 235, 461
 ADNI *see* Alzheimer's Disease Neuroimaging Initiative (ADNI)
aducanumab, 28
 amyloid PET scans, 30, 153
 animal studies, 74
 approved by the FDA, 1, 16
 Phase 1 trials, 95, 140, 143, 145
 Phase 2 trials (skipped), 158
 Phase 3 trials, 272
adverse events, 143–144, 175
 ARIA, 5, 114, 150, 154, 371, 379–380, 492–493
 cardiotoxicity, 143–144, 412
 and expanded access, 305
 off-target effects in preclinical studies, 3
advertising, 166–167
advocacy organizations, 12–13, 449–453
 funding operations, 450, 468, 481, 489–490
 for other forms of dementia, 217–218, 451
 see also individual organizations
African Americans
 low participation in trials, 211–212, 251, 254, 338
 risk of AD, 251
 see also diversity
AgeneBio Inc., 537
aging
 EEG changes, 420–421
 risk of AD, 78
Agora (web tool), 507
AHEAD study, 185–186, 510
AI *see* artificial intelligence
AI4AD project, 66
alcohol use, 401
aldolase A, 129
Alector Inc., 537
AlzGPS data mining tool, 63–64
Alzheimer, Alois, 25
Alzheimer Europe, 12–13
Alzheimer's Association, 12, 451, 486–494
 funding research, 468, 481, 489–490
 meetings sponsored by, 492–493
 trial recruitment, 252, 262, 493
Alzheimer's Clinical Trial Consortium (ACTC), 11, 182–187, 510
Alzheimer's Disease Assessment Scale – cognitive subscale (ADAS-cog), 281, 282–283, 284–285, 455
Alzheimer's Disease Composite Score (ADCOMS), 235, 461
Alzheimer's Disease Cooperative Study (ADCS), 177–178, 339, 432–433
Alzheimer's Disease International (ADI), 12, 451
Alzheimer's Disease Neuroimaging Initiative (ADNI), 9, 178, 180–181, 455–462, 510
Alzheimer's Disease Preclinical Efficacy Database (AlzPED), 509
Alzheimer's Disease Sequencing Project (ADSP), 63
Alzheimer's Drug Development Program (ADDP), 504–505
Alzheimer's Drug Discovery Foundation (ADDF), 13, 450, 482–484, 516
 Diagnostics Accelerator, 30, 468, 483
 partnership with the HDI, 49, 52
Alzheimer's Family Center (AFC), 451
Alzheimer's Foundation of America (AFA), 13, 451
Alzheimer's Prevention Initiative (API), 10, 397–398
Alzheimer's Prevention Registry (APR), 259–260
Alzheimer's Research and Prevention Foundation (ARPF), 451
Alzheimer's Therapeutic Research Institute (ATRI), 178–182
American Brain Foundation, 451
American Society for Clinical Investigation (ASCI), 48
AMP® AD (Accelerating Medicines Partnership® Program for Alzheimer's Disease), 63, 507–508, 510–511
amyloid beta (Aβ)
 Aβ oligomers binding to neurotransmitter sites, 515
 Aβ₄₂ and Aβ₄₂/Aβ₄₀ ratio, 95–96, 361–362, 363, 364–365, 369
 amyloid cascade hypothesis, 27, 34, 107
 amyloid plaques
 composed of Aβ₄₂/Aβ₄₃, 95–96
 and CSF Aβ levels, 98
 pathological marker of AD, 25, 27, 34
 PET, 109, 128, 377
 in rodent models, 106, 109
 animal models of amyloid pathology, 75–77, 79, 106

- in blood, 125, 351, 364–365, 369
- in CSF, 116, 152, 361–362, 363
- drugs targeting
 - BACE inhibitors, 181, 370, 381
 - CT1812, 186, 510, 518–520
 - glutaminy cyclase inhibitor (PQ912), 140, 142, 155–156, 423
 - GSI, 96
 - GSMs, 28, 96, 97–101
 - mAbs *see* anti-amyloid mAbs
- and EEG, 423
- iPSC models, 3, 96–97
- PET scans, 29–30, 385–386, 460, 483, 491
 - aducanumab therapy, 30, 153
 - and autopsy studies, 128
 - and fluid biomarkers, 366
 - IDEAS/New IDEAS studies, 493
 - reimbursement, 166
 - in rodents, 109
 - progression of AD, 377, 460
 - vaccination, 27, 75, 127–128
- amyloid precursor protein (APP), 34, 75–76
- amyloid-related imaging abnormalities (ARIA), 5, 114, 150, 154, 371, 379–380, 492–493
- amyotrophic lateral sclerosis (ALS), 66, 223
- Amyvid™ (florbetapir), 166, 483, 537–538
- angel investors, 468–469, 516
- animal models, 2–3, 38–39, 73–74, 80, 91, 106–107
 - cognitive assessment, 80–81
 - Drosophila*, 79
 - efficacy studies, 39, 74, 81–82
 - ethics, 91
 - familial AD, 75–77
 - imaging, 109–115
 - in vivo biomarkers, 107–118
 - late-onset AD, 77–79
 - MODEL-AD Center, 82–86, 107, 508–509
 - limitations, 106, 107, 111, 114–115, 117–118
 - pharmacokinetics, 39, 73–74, 85
 - primates, 79
- anti-amyloid mAbs, 27–28, 165–166
 - aducanumab *see* aducanumab
 - adverse events (ARIA), 5, 114, 150, 154, 371, 379–380, 492–493
 - Alzheimer's Association workgroup, 493
 - bapineuzumab, 27, 28, 370
 - crenezumab, 10, 28, 397–398
 - donanemab, 95, 474–475
 - gantenerumab, 28, 95, 370
 - lecanemab (BAN2401), 28, 185–186, 510
 - solanezumab, 27, 28, 179, 398
- anti-inflammatory drugs, 29, 128, 401, 529
- antisense oligonucleotides, 222–223, 225
- anti-sortilin mAb (AL001), 222, 223, 537
- anti-tau mAbs, 223–225
- antiviral drugs, 56–57
- apolipoprotein E4 (ApoE-4)
 - and AChE inhibitors, 408, 412, 413
 - and ethnicity, 400–401
 - risk factor for LOAD, 82, 276, 400–401
 - trial participant status, 4, 369
 - homozygotes, 10
- APP/PSEN1* mouse model, 76
- APP23* mouse model, 76
- arterial spin labeling MRI, 383
- ARTFL Consortium, 219
- artificial intelligence (AI), 62–70, 296–297
- artificial neural networks, 65–66
- assent, 433
 - see also* consent
- Association for Frontotemporal Degeneration (AFTD), 217–218
- atabecestat, 181
- ATP-binding cassette transporters (ABCs), 408, 412, 413
- attrition rates, 236, 253–254, 336, 338–339
- Australia, 459–460, 517
- autopsy studies, 127–128, 184, 251–252
- ivermectin, 97
- Avid Radiopharmaceuticals Inc. 537–538
- BACE inhibitors *see* beta-site APP cleaving enzyme (BACE) inhibitors
- bapineuzumab, 27, 28, 370
- basket trials, 226–227
- Bayesian adaptive randomization, 237
- behavioral changes, 7, 233–234, 272, 294, 508
 - cannabinoid treatment, 186, 510
- behavioral variant FTD, 216, 217
- beta-1-adrenergic receptor agonists, 446
- beta-site APP cleaving enzyme (BACE) inhibitors, 181, 370, 381
- big data, 62–64, 68–69, 505, 507–508
 - power consumption, 296
- Bingham, Kate, 525
- Bio-Hermes trial, 208–209, 212, 213
- biobanks, 123–124, 200, 458
- Bioinformatics and Data Management Core (BDMC), 83–85
- biologic therapies, 470
 - see also* monoclonal antibody (mAb) therapies
- biomarkers, 124–128, 212, 236
 - ACTC Biomarker Unit, 184
 - AMP® AD program, 510–511
 - animal studies, 107–118
 - in brain tissue, 127–128, 251–252
 - capacity for testing, 345–346
 - correlation with clinical outcomes, 243–244
 - in diagnosis, 29–30, 370, 375, 489
 - EEG, 422
 - fluid (CSF or blood), 30, 152, 363
 - MRI, 379, 380
 - PET, 29–30, 385–386
 - digital, 157, 212, 220, 292–295, 351
 - EEG, 145–146, 154, 418–426
 - fluid, 30, 125, 152, 236, 361–371
- ADNI specimens/data, 178, 458, 461
- animal models, 116–117
- blood, 351, 363–367, 369
- for FTLT, 220–221
- in primary care, 351
- reluctance to undergo lumbar puncture, 251, 345–346
- saliva, 126
- standardization, 363, 491–492
- urine, 125–126
- in FTLT, 220–222
- funding for discovery/development, 30, 468, 483, 506
- GAP programs, 208–209, 213
- gut microbiota, 127
- imaging, 173, 375–378, 391
 - see also* MRI; positron emission tomography
- in MCI, 5, 363, 377, 421–422
- “omics”, 128–129
- as outcome measures (treatment effects), 236, 370–371, 380–381, 388–389, 461
- Phase 1 trials, 144–146, 370
- Phase 2 trials, 4–5, 151, 152–154, 158, 461
- Phase 3 trials, 6, 461
- in preclinical AD, 488
- in primary care, 351
- regulatory guidance, 327, 390–391
- screening, 369, 379, 460–461
- statistical analysis, 243–244
- target engagement, 4, 370, 516
- biotechnology companies, 8–9, 162
 - Cognition Therapeutics Inc., 514–521, 538
- funded by the DDF, 529–530
- funded by NIH small business programs, 537–538
- IPOs, 469–470
- relationship with big pharma, 8, 163, 470
 - see also* pharmaceutical companies
- blood, biomarkers in, 30, 125, 363–367
- for FTLT, 220–221
- in primary care, 351
- in screening, 369
- standardization, 491
- blood–brain barrier (BBB), 3–4, 37, 39, 66
- blood flow imaging, 383, 386
- blood-oxygen-level-dependent (BOLD) fMRI, 112–114, 115, 383
- Bluefield Project to Cure FTD, 218
- Blueprint Neurotherapeutics Program, 505
- BPN-14770 (phosphodiesterase 4D inhibitor), 505, 538
- BPN-15606 (GSM), 97–98, 100
- brain atrophy *see* neurodegeneration
- brain health programs
 - Acti-v8 Your Brain, 209
 - Healthy Brains, 253, 261
- Brain Health Registry, 258–259
- BRAIN initiative, 467
- brain metabolism, 378, 388–389
- in rodents, 110–111, 115

Index

- brain tissue at autopsy, 127–128, 184, 251–252
BrightFocus Foundation, 451
Butler, Robert N., 26
butyrylcholinesterase (BuChE/*BCHE*), 406, 412, 413
- C3i Program, 540
C9orf72 expansion, 221, 222–223
CALERIE trial, 397
Cameron, David, 524
Canada, 11, 347
cancer research, 26, 465, 467, 498
cannabinoids, 186, 510
capacity to give consent, 273, 335–336, 433
capacity of healthcare systems, 344–347, 348–349
cardiotoxicity, 3, 143–144, 412
caregivers, 333–340, 486
 impact of COVID-19, 355
CBD Solutions, 218
CDR *see* Clinical Dementia Rating scale
Center for Strategic Philanthropy, 13, 496–497
Centers for Medicare and Medicaid Services, 166
Centiloid project, 491
cerebral blood flow imaging, 383, 386
cerebrospinal fluid (CSF)
 biomarkers, 125, 152, 236, 361–363, 370
 amyloid, 116, 152, 361–362, 363
 animal models, 116–117
 for FTLT, 220–221
 for neurodegeneration, 112, 116–117, 362
 standardization, 363, 491–492
 tau, 116, 152, 361, 362–363
 drug levels, 3–4
 lumbar puncture, 251, 312, 345–346
Cerevance Inc., 529–530
CGIC (Clinical Global Impression of Change), 286, 336
China
 approval of oligomannate, 29
 diagnosis of AD, 276
 regulatory agency (NMPA), 278, 320, 321, 324–325, 328
choline acetyltransferase (ChAT), 406
choline transporter (CHT), 406
cholinergic agents *see*
 acetylcholinesterase (AChE)
 inhibitors
cholinergic hypothesis, 26, 405–408, 423
cholinergic receptors, 407–408, 412
Citizen Scientist Awards, 209
Clinical Data Interchange Standards Consortium (CDISC), 237
Clinical Dementia Rating scale (CDR)
 CDR plus NACC FTLT, 220
 CDR – sum of boxes (CDR-sb), 6–7, 234
Clinical Global Impression of Change (CGIC), 286, 336
clinical outcomes, 6–7, 234–236
 cognitive *see* cognitive function
 correlation with biomarkers, 243–244
 in FTLT, 219–220
 functional, 7, 234, 235, 294, 336
 global (composite) measures, 6–7, 234–236, 286, 287, 336, 461
 study partners’ role in assessment, 336–337, 339–340
clinical raters, 173, 176, 208, 314
clinical research associates (CRAs), 312–313, 316
clinical research coordinators (CRCs), 172–173
Clinical Trials in Alzheimer’s Disease (CTAD) conferences, 178–179
Clinical Trials Transformation Initiative (CTTI), 268
Clinical Trials.gov website, 252–253
Cognition Therapeutics Inc., 514–521, 538
cognitive function, 281–289
 assessment, 26–27
 ADAS-cog, 281, 282–283, 284–285, 455
 digital, 157, 212, 220
 in the EPAD LCS trial, 199
 in FTLT, 219–220
 in global trials, 276
 MMSE, 281–282
 NTB, 284, 286
 in Phase 1 trials, 145, 286–287
 in preclinical AD, 7, 156, 235
 in primary care, 350
 in rodent models, 80–81
 in severe dementia, 7
 study partners’ input, 336–337, 340
 circuit integrity, 4
 cognitive reserve, 277
 cognitive resilience, 508
 EEG changes correlated with, 421–422, 423
 regulatory agencies’ views of tests, 26–27, 285–286
Cognitive Functional Composite (CFC), 287
Cohen’s *d*, 240
commercial trial sites, 171
commercialization
 by pharmaceutical companies, 165–167
 SPARK projects, 444, 446
Commercialization Readiness Pilot (CRP) program, 540
communication with the public, 14
compassionate use, 302, 306
 right to try laws, 306
 see also expanded access
computerized testing of cognition, 157, 212, 220
 see also digital technologies
conditioned extraction, 515–516
conferences
 Alzheimer’s Association-sponsored, 492–493
 CTAD, 178–179
 GAP-sponsored, 208
 organized by pharmaceutical companies, 167
confidentiality of patient data, 297, 312, 396
confirmation bias, 241
conflicts of interest (COIs), 431–433
 in DSMB members, 269
 inside IRBs, 430, 432
consent, 138, 174, 273, 335–336, 433–434
CONSORT criteria, 15
Consortium of Canadian Centres for Clinical Cognitive Research (C5R), 11
contract research organizations (CROs), 12, 163, 309–317
 COVID-19 pandemic disrupting trials, 357
 in the EPAD project, 202
 funded by non-profit organizations, 498
 site selection, 172, 311
convertible debt, 528
corticobasal syndrome (CBS), 217, 218
costs
 of AD healthcare, 348, 349, 465, 486, 503
 of drug development, 62, 301, 437, 465, 533
 of PET screens, 166, 369
covariate analysis, 241–242
COVID-19 pandemic
 disruption to trials, 176, 195, 211, 315–316, 354–358
 remote working, 278, 355, 356, 358
crenezumab, 10, 28, 397–398
Creutzfeldt–Jakob disease (CJD), 362
Critical Path Institute (C-Path), 11, 326
CROs *see* contract research organizations
CSF *see* cerebrospinal fluid
CT1812, 514, 516–518, 538
 mechanism of action, 518–520
 Phase 1 trials, 140, 142, 517
 Phase 2 trials, 186, 510, 518, 520
CTAD conferences, 178–179
CTSA Collaborative DSMB Workgroup, 269
CuraSen Therapeutics Inc., 445–446
Cure Alzheimer’s Fund (CAF), 13, 450, 451
CurePSP, 218
Cures Act (USA), 305, 320
cystic fibrosis, 482, 497
cytochrome P450 enzymes (CYPs)
 and AChE inhibitors, 408, 412, 413
 ethnic differences, 277
 and memantine, 414
 multifactorial treatments, 414
- data management, 237–238
 ACTC unit, 184
 biobanks, 124
 data management plans, 238
 digital technologies, 296–297
 EEG, 420, 426
 global trials, 278
 interim analysis of trial results, 163–164, 236–237, 271–272
 security of data, 297, 396
 sharing data, 395–402, 458–459, 506, 507, 511–512

- statistical analysis, 240–244
 - EPAD proof-of-concept platform, 202–203
- data safety monitoring boards (DSMBs), 163–164, 266–273, 434
- databases, 62–64
 - AD Knowledge Portal, 63, 83, 507
 - ADNI, 9, 458–459
 - AlzPED (preclinical studies), 509
 - GAAIN, 395–402
- davunetide, 225
- death, 31, 488
- Decentralized Trials and Research Alliance (DTRA), 452
- deep learning, 65–66
- deepDThet, 67
- default mode network (DMN), 112–114, 383
- delivery of future treatments, 343–352
- dementia
 - irreversible, 343–344
 - stages in AD, 488
 - see also* clinical outcomes
- Dementia Discovery Fund (DDF), 473, 524–528, 529–532
- diabetes mellitus, 30, 78–79
- diagnosis of AD, 4–5, 344, 487–489
 - biomarkers, 29–30, 370, 375, 489
 - EEG, 422
 - fluid (CSF or blood), 30, 152, 363
 - MRI, 379, 380
 - PET, 29–30, 385–386
 - in the early stages, 166, 488
 - global trials, 276, 277
 - by primary care physicians, 348–349
- Diagnostics Accelerator program, 30, 468, 483
- DIAN-TU trial, 9–10, 398
- diet, 79, 397
 - nutritional supplements, 423–424
- diffusion tensor imaging (DTI) MRI, 382–383
- digital technologies, 292–299
 - biomarkers, 292–295, 351
 - cognitive testing, 157, 212, 220
 - regulatory matters, 295–296
 - remote working during the COVID-19 pandemic, 278, 355, 356, 358
 - smartphones, 264, 294
 - tele-care, 350
 - tele-monitoring, 292–295, 313–314
 - validation, 296–297, 358
- direct to consumer advertising, 167
- dissent, 433
- diversity
 - in IRB membership, 431
 - in trial participants, 17–18, 184, 209, 211–212, 250–253, 338
 - global trials, 276, 277
 - and use of digital technologies, 264, 294, 297
 - in the workforce, 501–502, 510
- Dominantly Inherited Alzheimer's Network Treatment Unit (DIAN-TU), 9–10, 398
- donanemab, 95, 474–475
- donepezil, 408–412
- dopamine D2 receptor antagonists, 35–36
- dopamine transport, 390
- dosage
 - animal trials (NOAEL), 3
 - Phase 1 trials (MTD), 3, 137, 141
 - Phase 2b trials (dose-finding), 150, 151
- Down syndrome
 - ACTC-DS, 186, 510
 - iPSCs derived from patients, 97
 - mouse model, 446
- dropout rates, 236, 253–254, 336, 338–339
- Drosophila* model, 79
- drug-development process, 1–19, 162–163
- drug-development tools (DDTs), 326
- drug discovery, 2, 7–9
 - in academia, 34–39
 - and AI, 62–70
 - Cerevance platform, 529–530
 - Cognition Therapeutics platform, 514–516
 - repurposing, 54–59, 67, 97, 225–226, 483, 505
 - see also* target identification
- DrugBank database, 63
- DrugCentral database, 63
- DSMBs *see* data safety monitoring boards
- dual-role consent, 433–434
- dulaglutide, 57
- duration of clinical trials, 5, 233, 455
- early adopters of new therapies, 165–166
- EARLY study, 181
- early termination of a trial, 163–164, 237, 271–272, 357–358, 434
- early-onset AD (EOAD)
 - familial AD, 34, 45
 - A β_{42} in pathogenesis, 95–96, 99
 - animal models, 75–77
 - iPSCs derived from EOAD patients, 96–97, 100–104
 - PSEN1* mutations, 10, 102–104
 - sporadic AD (LEADS study), 182
- education *see* training
- EEG *see* electroencephalography
- effect size, 240, 288, 339
- efficacy
 - in animal models, 39, 74, 81–82
 - clinical measures, 6–7, 234–236
 - early trial termination due to benefit, 164, 272
 - proof-of-concept studies, 151
- electricity consumption of digital devices, 296
- electroencephalography (EEG), 145–146, 154, 418–426
 - analysis, 419–420, 424–426
 - pathology, 420–423
- EMA *see* European Medicines Agency
- ending a trial, 175
 - early, 163–164, 237, 271–272, 357–358, 434
- entrepreneurs, 469, 539–540
- enzyme inhibitors/modulators, 28
- BACE inhibitors, 181, 370, 381
- GSIs, 96, 271
- GSMs, 28, 96, 97–101
- HDAC inhibitors, 222
- phosphodiesterase 4D inhibitor (BPN-14770), 505, 538
- rho-kinase (ROCK) inhibitors, 54–55, 226
- tyrosine kinase inhibitors, 181
- enzyme-linked immunosorbent assay (ELISA), 81
- EOAD *see* early-onset AD
- EPAD *see* European Prevention of Alzheimer's Disease (EPAD)
- epidemiology
 - AD, 1, 275, 343, 486
 - in the USA, 31, 45, 465
 - FTLD, 216
- epigenetics, 414
- episodic memory, 281, 282
- equity (common and preferred), 528
- ethics
 - animal research, 91
 - conflicts of interest, 431–433
 - in DSMB members, 269
 - inside IRBs, 430, 432
 - consent, 138, 174, 273, 335–336, 433–434
 - early trial closure, 163–164, 271–272, 434
 - expanded access, 305–306
 - IRBs, 305–306, 429–434
 - Phase 1 trials, 135, 138
- ethnicity
 - APOE-4*, 400–401
 - diversity in IRB membership, 431
 - diversity in trial recruitment, 17–18, 184, 209, 211–212, 250–253, 338
 - global trials, 276, 277
 - use of digital technologies, 264, 294, 297
 - diversity in the workforce, 501–502, 510
 - globalization of trials, 276, 277
 - risk of AD, 251, 400–401
- Europe
 - ADNI, 459
 - advocacy organizations, 12–13
 - IMI, 11–12, 190, 195, 326
 - Neuronet, 11–12, 195
 - PRIME scheme, 320
 - regulations *see* European Medicines Agency
 - reimbursement, 166
- European Medicines Agency (EMA), 277–278
 - on cognitive testing, 285
 - on compassionate use, 306
 - on disease modification trial designs, 246, 277–278
 - interactions with industry during drug development, 321, 323, 325–327
 - European Prevention of Alzheimer's Disease (EPAD), 10–11, 190–205
 - collaboration between participants and trialists, 10–11, 196
 - industry participation, 195–196
 - longitudinal cohort study (LCS), 192, 198–200
 - proof-of-concept trials, 10, 190–191, 192, 200–204
 - register, 191–192, 196–197

Index

- European Medicines Agenc (cont.)
 structure and organization, 192–195
 TDC network, 192, 198
executive function, 288
exenatide, 57–58
exosomes, 129
expanded access (EA), 301–308
extended-connectivity fingerprints (ECFPs), 64
- failure rates in drug trials, 465, 471, 480, 524
false negatives (type II error), 37, 245–246
false positives (type I error), 37, 245
 in cognitive testing, 287
famciclovir, 56–57
familial AD, 34, 45
 A β_{42} , in pathogenesis, 95–96, 99
 animal models, 75–77
 iPSCs derived from EOAD patients, 96–97, 100–104
 transcriptomics of *PSEN1* mutations, 102–104
fasudil, 54–55, 226
FDA *see* Food and Drug Administration (FDA)
FDG PET imaging, 110–111, 376, 377, 378, 388–389
fecal microbiome transplants, 127
fellowships, 500
females
 in Phase 1 trials, 136
 risk of AD, 78, 251, 401
 rivastigmine, 413
fibrin (target), 529
financial issues
 costs
 of AD healthcare, 348, 349, 465, 486, 503
 of drug development, 62, 301, 437, 465, 533
 of PET screens, 166, 369
 license agreements, 40–41
 payments to study partners, 340
 reimbursement, 166, 211
 see also funding
fingerprint representation of molecules, 64
first-in-human (FIH) trials *see* Phase 1 clinical trials
Fisher Center for Alzheimer's Research Foundation (FCARF), 451
florbetaben, 109, 456
florbetapir (Amyvid™), 166, 483, 537–538
flortaucipir, 109, 456
flow cytometry, 82
fluorescence-activated cell sorting, 82
Food and Drug Administration (FDA)
 on biomarkers, 277, 327, 390–391
 on cognitive tests, 285–286
 on digital technologies, 295–296
 on disease modification trial designs, 246
 on DSMBs, 267, 268
 on expanded access, 301–303, 305–306, 307
 guidelines, 26–27
 interactions with industry during drug development, 13–14, 321, 322, 325–327
 organization, 328
 on trial recruitment, 251
4 R Tauopathy Neuroimaging Initiative (4RTNI), 219
French National Alzheimer Database, 402
Frontotemporal Dementia Initiative (FPI), 219
frontotemporal lobar degeneration (FTLD), 216–227
 advances in trial design, 226–227
 biomarkers, 220–222
 clinical outcomes, 219–220
 drug development, 222–226, 537
 organizations involved in research, 217–219
 pathology, 216–217
functional measures of impairment, 7, 234, 235, 336
 correlation with cognition, 285–286
 passive monitoring, 294
functional MRI (fMRI), 112–114, 115, 383
funding, 7–9, 46, 465–475
 academic timescales, 41
 advocacy/non-profit organizations, 450, 468, 481, 489–490
 angel investors, 468–469, 516
 Cognition Therapeutics Inc., 514–515, 516, 518, 538
 conflicts of interest, 432
 drug development costs, 62, 301, 369, 465, 533
 IPOs, 469–470
 NIH–NIA, 16, 86, 452, 466–468, 480–481, 503–512, 533–541
 pharmaceutical companies, 62, 465, 470, 481
 philanthropy, 13, 468, 496–502
 portfolio approach (megafunds), 472
 public–private partnerships, 472–473
 royalty investments, 473–474
 small businesses, 467–468, 516, 533–541
 SPARK program, 441
 valley of death, 9, 46, 147, 474, 480, 481, 497–499, 517–518
 venture capital, 8–9, 469, 481, 524–532
 venture philanthropy, 13, 473, 481–484, 497–499
futility analysis, 164, 237, 272
Fyn tyrosine kinase, 181
- GAAIN *see* Global Alzheimer's Association Interactive Network (GAAIN)
gamma-aminobutyric acid A receptor, alpha 5 (GABA-A $\alpha 5$) receptor, 537
galantamine, 409, 412–413
gamma-secretase inhibitors (GSIs), 96, 271
gamma-secretase modulators (GSMs), 28, 96, 97–101
gantenerumab, 28, 95, 370
GAP *see* Global Alzheimer's Platform (GAP)
Gates, Bill, 468, 473, 490, 501
gender
 participants in Phase 1 trials, 136
 risk of AD, 78, 251, 401
 rivastigmine, 413
GeneMatch program, 259
Genetic Frontotemporal Dementia Initiative (GENFI), 219
genetics, 405
 ADNI data, 458
 APOE-4, 10, 82, 276, 400–401
 early-onset AD, 10, 34, 45
 DIAN study, 9–10
 epigenetics, 414
 FTLD, 221, 222
 genomic data, 62–63, 66, 128–129
 pharmacogenomics, 277, 404–415
 AChE inhibitors, 404, 408–413
 memantine, 413–414
 risk genes as targets, 58, 66
 risk-lowering mutation, 519
genome-wide association studies (GWAS), 66, 128–129
Germany, 347, 349
Global Alzheimer's Association Interactive Network (GAAIN), 395–402, 491
Global Alzheimer's Platform (GAP), 11, 191, 207–214
Global Biomarker Standardization Consortium (GBSC), 491–492
global (composite) outcome measures, 6–7, 234–236, 286, 287, 336, 461
globalization of trials, 275–279, 314–315
glucagon-like peptide 1 (GLP-1) receptor agonists, 57–58
glutaminy cyclase inhibitor (PQ912), 140, 142, 155–156, 423
Golden Seeds (investors), 516
GRN mutations, 221, 222
group sequential designs (GSD), 237
GSIs *see* gamma-secretase inhibitors
GSMs *see* gamma-secretase modulators
gut microbiota, 127
GV-971 (oligomannate), 29, 127, 278
- half-life of drugs, 144
Harrington Discovery Institute, 46–53, 483–484, 499
head trauma, 180–181, 366, 401
healthcare systems
 introduction of new treatments, 343–352
 reimbursement, 166
Healthy Brains, 253, 261
heart disease research, 26
herpes viruses, 56
high content analysis, 2
high-throughput screening, 2, 7–9, 36–38
hippocampus
 and cognitive decline in rodents, 80–81
 volume reduction, 112, 236, 380–381

- Hispanic Americans, 211–212, 251, 400–401
- histone deacetylase (HDAC) inhibitors, 222
- history of AD and AD drugs, 25–31
- home monitoring, 292–295, 313–314
- hospitals hosting trial sites, 171
- human-induced pluripotent stem cells (hiPSCs), 3, 36, 96–97, 100–104, 126–127
- human resources *see* staff
- huperazine A, 411, 413
- hyperphosphorylated tau *see* p-tau
- IBM Watson, 66
- IDEAS/New IDEAS studies, 493
- imaging, 173, 375–378, 391
- ACTC units, 184
- ADNI, 9, 180–181, 456, 458, 510
- regulatory guidance, 390–391
- see also* MRI; positron emission tomography
- immunohistochemistry, 81
- immunotherapy *see* monoclonal antibody (mAb) therapies; vaccination
- IMPACT-AD training course, 185, 511
- in vivo testing *see* animal models
- incurability of dementia, 343–344
- expanded access, 301–308
- IND *see* investigational new drug
- induced pluripotent stem cells (iPSCs), 3, 36, 96–97, 100–104, 126–127
- inflammation
- animal models, 77–78
- anti-inflammatory drugs, 29, 128, 401, 529
- and gut microbiota, 127
- imaging, 381, 389–390
- TREAT-AD Center research, 86–91
- informatics *see* data management
- informed consent, 138, 174, 273, 335–336, 433–434
- initial public offering (IPO), 469–470
- Innovation Corps at NIH program, 539–540
- Innovative Medicines Initiative (IMI), 11–12, 190, 195, 326
- see also* European Prevention of Alzheimer's Disease (EPAD)
- inositol polyphosphate-5-phosphatase D (INPP5D), 88
- institutional review boards (IRBs), 305–306, 429–434
- insulin, 181
- interdisciplinary research, 500
- interim analysis, 163–164, 236–237, 271–272
- International Alzheimer's and Related Dementias Research Portfolio (IADRP), 490
- international organizations
- ADI, 12, 451
- GAAIN, 395–402, 491
- worldwide ADNI, 459–460
- International Psychogeriatric Association, 452
- International Society for CNS Clinical Trials and Methodology (ISCTM), 452
- International Society for CNS Drug Development (ISCDD), 452
- investigational new drug (IND), 13
- expanded access, 301–308
- investigators,
- conflicts of interest, 432
- training, 18, 184, 185, 279
- iPSCs *see* induced pluripotent stem cells (iPSCs)
- IPO *see* initial public offering
- IRBs *see* institutional review boards
- 305–306, 429–434
- IUSM–Purdue TREAT-AD Center, 86–91
- Japan
- ADNI, 460
- dementia healthcare, 350
- prevalence of dementia, 343
- regulatory agency (PDMA), 320–321, 324, 325, 328
- Katzman, Robert, 25
- key opinion leaders (KOLs), 165–166
- lanabecestat, 381
- language
- ADAS-cog tests, 282
- PPA, 216
- Lasker, Albert Jr., 26
- late-onset AD (LOAD), 45–46
- animal models, 77–79, 82–86, 107, 508–509
- Latinx ethnicity, 211–212, 251, 400–401
- Lauder family, 450, 468, 516
- launching a new drug, 165–167
- LEADS study, 182
- LEARN study, 180
- lecanemab (BAN2401), 28, 185–186, 510
- LEFTTDS Consortium, 219
- letters of support, 326–327
- Leukemia and Lymphoma Society, 498
- levetiracetam, 537
- Lewy Body Dementia Association (LBDA), 451
- LiBBY trial, 186, 510
- libraries of compounds for screening, 2, 37, 515–516
- licensing agreements, 40–41
- lifestyle
- diet, 79, 397
- interventions, 30, 493
- light gradient boosting machine model, 66
- lipopolysaccharide (LPS), 77
- liraglutide, 57–58
- lithium, 76, 226
- LMTM (phenothiazine), 225–226
- LOAD *see* late-onset AD
- location of trial sites, 171
- locus coeruleus, 445–446
- Long Island Alzheimer's and Dementia (LIAD) Center, 451–452
- long-term care facilities during the COVID-19 pandemic, 355, 358
- lumbar puncture, 251, 312, 345–346
- M²OVE-AD program, 508
- machine learning, 64–66, 296–297
- magnetic resonance spectroscopy (MRS), 384
- males, 413
- MAPT (microtubule-associated protein tau) gene, 107, 216
- marketing, 165, 166–167
- marketing authorization, 327
- maximum recommended starting dose (MRSD), 136–137
- maximum tolerated dose (MTD), 3, 137, 141
- MCI *see* mild cognitive impairment
- media coverage, 14, 174, 260
- Medicare, 166, 211, 486
- meetings *see* conferences
- megafunds, 472
- memantine, 77, 410, 413–414, 423
- memory, assessment
- ADAS-cog, 281, 282, 284–285
- NTB, 284
- in rodents, 80–81
- self-reported memory loss, 401
- memory clinics, 349
- men, 413
- menopause, 78
- meta-analysis, 401
- metabolomics, 129
- microbiota of the gut, 127
- microglial cells, 34, 77
- microtubule stabilization, 225
- mild cognitive impairment (MCI)
- in ADNI, 456, 462
- capacity to give consent, 335–336
- cognitive/functional assessment, 234, 455
- EEG changes, 421–422
- fluid biomarkers, 5, 363, 377
- prevalence, 343
- recruitment to trials, 335, 338
- SNAP-MCI (plus suspected non-amyloid pathology), 401
- stage of AD, 6, 455, 488
- study partners, 333, 335, 338
- TRC-PAD program, 181, 253, 262–264
- milestones, 528–529, 534
- Milken Institute Center for Strategic Philanthropy, 13, 496–497
- Milken, Michael, 496
- Mini-Mental State Examination (MMSE), 281–282
- minority groups *see* diversity
- Mixed Model Repeated Measures (MMRM), 236, 240
- MMSE *see* Mini-Mental State Examination
- Mochly-Rosen, Daria, 440
- MODEL-AD Center (Model Organism Development and Evaluation for Late-Onset AD), 82–86, 107, 508–509
- models of disease *see* animal models; stem cells (iPSCs)
- models, statistical, 240
- monitoring
- remote monitoring of participants, 292–295, 313–314
- of trial sites, 174–175, 312–314

Index

- monoclonal antibody (mAb) therapies, 3
 anti-amyloid *see* aducanumab; anti-amyloid mAbs
 anti-sortilin, 222, 223, 537
 anti-tau, 223–225
 need for infusion facilities, 165–166
Morris water maze (MWM), 80
motion tracking in animal imaging studies, 114–115
motor neuron disease with FTLN, 217
mouse models *see* animal models
MRI, 5, 111–114, 376, 379–382
 ADNI data, 458, 461
 arterial spin labeling, 383
 in awake animals, 115
 DTI, 382–383
 fMRI, 112–114, 115, 383
 in FTLN, 221–222
 monitoring for ARIA, 5, 114, 154, 371, 379–380
 MRS, 384
 neurodegeneration, 111–112, 153–154, 376, 377, 380–381, 461
MTD *see* maximum tolerated dose
Multi-Arm Multi-Stage (MAMS) trial design, 237
Multidomain Impairment Rating (MIR), 220
multiple ascending dose (MAD)
 tolerance studies, 3, 135, 140–143
multiple sclerosis, 67
multiplex assays, 81

N-acetylaspartate (NAA), 384
National Alzheimer's Project Act (NAPA) (USA), 449, 467, 503, 513–514
National Institute on Aging (NIA) (USA), 26, 466–467, 503–512, 535–536
 NIA-AA 2011 diagnostic guidelines, 487–488
National Institute for Health and Care Excellence (NICE) (UK), 166
National Institutes of Health (NIH) (USA), 26
 on conflicts of interest, 432
 on DSMBs, 268
 funding of research, 16, 86, 452, 466–468, 480–481, 503–512
 small business programs, 467–468, 516, 533–541
 on IRBs, 430–431
National Medicines Products Administration (NMPA) (China), 278, 320, 321, 324–325, 328
NETSeq platform (Cerevance), 529–530
neural circuits, 4
 see also electroencephalography
neuritic (amyloid) plaques
 composed of A β_{42} /A β_{43} , 95–96
 and CSF A β levels, 98
 pathological marker of AD, 25, 27, 34
 PET, 109, 128, 377
 in rodent models, 106, 109

neurodegeneration (N)
 EEG changes, 423
 FDG PET, 110–111, 376, 377, 378, 388–389
 fluid biomarkers, 370–371
 in blood, 366–367
 in CSF, 112, 116–117, 362
 hippocampal volume reduction, 112, 236, 380–381
 MRI, 111–112, 153–154, 376, 377, 380–381, 461
 progression of AD, 378, 388
neurofibrillary tangles, 27, 45, 377–378
 see also tau
neurofilament light chain (NfL), 364
 in ARIA, 371
 neurodegeneration marker in AD, 112, 116–117, 367
 in other neurodegenerative disorders, 221, 369, 370
neuroinflammation *see* inflammation
neurologists, 165–166, 349
Neuronet, 11–12, 195
Neuropsychological Test Battery (NTB), 284, 286
neurotransmitters
 acetylcholine, 26, 405–408
 gamma-aminobutyric acid A receptor, alpha 5 (GABA-A α 5) receptor, 537
 not a target, 517
neurovascular coupling (BOLD signals), 112–114, 115, 383
new drug application (NDA), 13
NIA *see* National Institute on Aging
NIAGADS genomics database, 63
nicotine, 181
nicotinic ACh receptors, 407–408, 412
NIH *see* National Institutes of Health
Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research assessment, 220
nimodipine, 222
N-methyl-D-aspartate glutamate receptor inhibitor (memantine), 77, 410, 413–414, 423
no observed adverse event level (NOAEL) in animal trials, 3, 136–137
non-clinical assessment of potential drugs
 animal models *see* animal models
 Cerevance platform, 529–530
 Cognition Therapeutics platform, 514–516
 iPSCs, 3, 36, 96–97, 100–104, 126–127
 NIH programs, 504–505
non-profit organizations, 12–13, 449–453
 funding, 450, 468, 481, 489–490
 partnering with for-profit organizations, 473
 venture philanthropy, 13, 473, 481–484, 497–499
for other forms of dementia, 217–218, 451
supporting academics, 498–499

see also individual organizations
non-steroidal anti-inflammatory drugs (NSAIDs), 29, 128, 401
novel object recognition, 80
nursing homes during the COVID-19 pandemic, 355, 358
nutritional supplements, 423–424

obesity, 79
Office of Small Business Research (OSBR) (NIH), 539, 540
oligomannate (GV-971), 29, 127, 278
“omics” data, 62–63, 66, 128–129, 507–508
online advertising, 167
open science, 506, 511–512
 ADNI, 458–459
 AMP® AD, 507
 GAIA platform, 395–402, 491
organic brain syndrome (OBS), 25
outcome measures
 biomarkers, 236, 370–371, 380–381, 388–389, 461
 clinical outcomes *see* clinical outcomes; cognitive function
Oxford–Harrington Rare Disease Centre (OHC), 51

p-tau (hyperphosphorylated tau)
 in blood, 351, 364, 365–366, 369
 in CSF, 116, 152, 361, 362–363
 EEG changes, 423
 in FTLN, 220–221
 inhibitors of phosphorylation, 36
 mouse models, 76–77
 pathology of AD, 45, 76, 362–363, 365–367, 377–378
 screening of trial participants, 152, 369
p-value, 241
pacemakers, 174
Parkinson's disease, 58, 213–214
Part the Cloud program, 490
participants in clinical trials
 as collaborators in trials, 10–11, 196
 consent, 138, 174, 273, 335–336, 433–434
 and the COVID-19 pandemic, 355, 356
 diversity, 17–18, 184, 209, 211–212, 250–253, 338
 and use of digital technologies, 264, 294, 297
 and early termination of a trial, 434
 EPAD project, 10–11, 191, 196–197, 199–200
 for FTLN subtypes, 217
 GAP programs, 209, 210–212
 global trials, 275–277
 Phase 1, 3, 135–136, 138, 150
 Phase 2, 4, 151
 Phase 3, 5–6
 recruitment *see* recruitment of trial participants
 retention, 236, 253–254, 336, 338–339
 study populations, 150, 151, 232–233
 transport, 209
 patents, 440

- pathology of AD, 1, 45, 487
 - A β oligomers binding to neurotransmitter sites, 515
 - A β_{42} and A β_{42} /A β_{40} ratio, 95–96, 361–362, 363, 364–365, 369
- amyloid cascade hypothesis, 27, 34
- animal models, 75–78, 79–80, 106–107
- described by Alzheimer, 25
- EEG, 420–423
- genes, 405
- progression, 377–378, 420–422, 460
- tau, 27, 45, 76–77, 362–363, 365–367, 377–378
 - see also* neuritic (amyloid) plaques; neurodegeneration
- pathology of FTLT, 216–217
- patients
 - patient journey, 344
 - primary care, 348–349–350
 - stratification by AI, 67
 - see also* participants in clinical trials
- PDAPP mouse model, 75–76
- percent slowing effect size, 238–239, 240
- perfusion imaging, 383, 386
- personalized medicine, 69, 531–532
- PET *see* positron emission tomography
- pharmaceutical companies, 162–168
 - active in AD drug research and development, 16, 34, 470, 513
 - commercialization activities, 165–167
 - COVID-19 pandemic disrupting trials, 357
 - and expanded access/compassionate use, 304–305, 306
 - funding drug development, 62, 465, 470, 481
 - interactions with regulatory authorities, 164–165, 320, 321–327
 - SPARK program advisors, 438, 441, 446–447
 - staff, 167
 - working with other organizations/individuals, 163
 - academic institutions, 8, 39–41, 171, 175
 - ADNI, 9, 178, 180–181, 455–462
 - EPAD, 195–196
 - opinion leaders, 165
 - small biotech companies, 8, 163, 470
 - see also* biotechnology companies
- Pharmaceuticals and Medical Devices Agency (PMDA) (Japan), 320–321, 324, 325, 328
- pharmacodynamics (PD), 73, 141, 145
- pharmacogenomics, 277, 404–415
 - AChE inhibitors, 404, 408–413
 - memantine, 413–414
- pharmacokinetics (PK)
 - AI can predict, 62, 66
 - animal models, 39, 73–74, 85
 - enzymes involved, 408
 - CYP variants, 277, 408, 412–412, 413, 414
 - Phase 1 trials, 137, 144
 - see also* pharmacogenomics
 - pharmacologically active dose (PAD), 136
 - Phase 1 clinical trials, 3–4, 135–147, 150, 162–163
 - of aducanumab, 95, 140, 143, 145
 - biomarkers, 144–146, 370
 - of CT1812, 140, 142, 517
 - funding, 9, 147, 504–505
 - MAD tolerance studies, 3, 135, 140–143
 - outcomes, 143–145, 286–287
 - participants, 3, 135–136, 138, 150
 - SAD tolerance studies, 3, 138–140
 - safety, 137, 139, 141, 143–144, 146–147
 - Phase 2 clinical trials, 4–5, 150–159, 163
 - adaptive trial designs, 10–11, 16–17, 151, 227, 236–237, 253
 - basket trials, 226–227
 - biomarkers, 4–5, 151, 152–154, 158, 461
 - cognitive outcomes, 156–157, 158–159, 287
 - of CT1812, 186, 510, 518, 520
 - dose-finding (phase 2b), 150, 151
 - drug pipeline, 157
 - EPAD proof-of-concept platform, 10, 190–191, 192, 200–204
 - participants, 4, 151
 - proof of concept (Phase 2a), 4–5, 151
 - safety, 152, 154
 - Phase 3 clinical trials, 5–7
 - biomarkers, 6, 461
 - cognitive outcomes, 6–7, 287–288
 - in FTLT, 227
 - Phase 4 clinical trials, 7
 - phenserine, 55–56
 - philanthropy, 13, 468, 496–502
 - venture philanthropy, 13, 473, 481–484, 497–499
 - see also* Alzheimer's Drug Discovery Foundation (ADDF)
 - 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma-2 (PLCG2), 88–91
 - phosphodiesterase 4D inhibitor (BPN-14770), 505, 538
 - physicians
 - dual-role consent, 433–434
 - involvement in expanded access, 304, 306
 - in primary care, 348–351
 - specialists, 345, 349
 - pimavanserin, 272
 - Pittsburgh (PA), local funding, 514–515
 - placebo group
 - data from previous trials, 238
 - pooled/shared, 202, 237
 - planning dementia care, 347–351
 - plasma biomarkers *see* blood, biomarkers in
 - plasma-derived therapeutic factors, 226
 - “play the winner” design, 237
 - polyriboinosinic-polyribocytidilic acid, 77
 - portfolio funding, 472
 - positron emission tomography (PET), 376, 377, 384–385, 390
 - ADNI data, 456, 458, 460, 461
 - amyloid PET scans, 29–30, 385–386, 460, 483, 491
 - aducanumab therapy, 30, 153
 - and autopsy studies, 128
 - and fluid biomarkers, 366
 - IDEAS/New IDEAS studies, 493
 - reimbursement, 166
 - in rodents, 109
 - capacity constraints, 345
 - costs, 369
 - FDG PET, 110–111, 376, 377, 378, 388–389
 - inflammation, 389–390
 - in Phase 2 trials, 153, 461
 - in rodents, 109–111
 - awake, 115
 - tau, 109–110, 153, 386–388, 461
 - tracers, 386, 387, 388, 389–390, 456, 483, 537–538
 - treatment effects, 388–389
 - post-marketing studies (phase 4), 7
 - power consumption of digital devices, 296
 - power (statistics), 236, 245–246
 - PPA *see* primary progressive aphasia
 - PQ912 (glutaminy cyclase inhibitor), 140, 142, 155–156, 423
 - precision medicine, 69, 531–532
 - preclinical AD, 488
 - A3/A45 trials, 185–186, 510
 - A4 trial, 179, 250, 338, 401, 511
 - cognitive assessment, 7, 156, 235
 - study partners, 333, 335, 336–337, 338, 340
 - preclinical assessment of potential drugs
 - animal models *see* animal models
 - Cerevance platform, 529–530
 - Cognition Therapeutics platform, 514–516
 - iPSCs, 3, 36, 96–97, 100–104, 126–127
 - NIH programs, 504–505
 - Preclinical Testing Core of MODEL-AD, 85–86, 509
 - PrePAD tool, 197
 - preparedness for new treatments, 344–352
 - presenilin (*PSEN*) mutations, 10, 406
 - iPSCs, 96, 102–104
 - mouse models, 76
 - prevention, 99–100, 187
 - lifestyle interventions, 30, 493
 - not cure, 343–344
 - trials, 151
 - A4, 179, 250, 338, 398, 401, 511
 - API, 10, 397–398
 - cognitive assessment, 7, 156
 - DIAN-TU study, 9–10, 398
 - TRC-PAD, 181, 253, 262–264
 - see also* European Prevention of Alzheimer's Disease (EPAD)
 - primary care, 348–351
 - screening for AD, 369
 - primary progressive aphasia (PPA), 216, 217
 - primate models, 79
 - PRIME scheme, 320

Index

- principal investigators (PI), 172
- prodromal AD *see* mild cognitive impairment (MCI)
- progranulin, 221, 222, 537
- progression of AD, 5–6, 233, 388, 487–489
 - biomarkers, 377–378, 460
 - EEG changes, 420–422
- progressive supranuclear palsy (PSP), 217, 218, 223–226
- proof-of-concept (POC) trials (Phase 2a), 4–5, 151, 287
- PSEN* *see* presenilin (*PSEN*) mutations
- psychiatric symptoms, 7, 233–234, 272, 508
 - cannabinoid treatment, 186, 510
- psychiatrists, 349
- public opinion, 14
- public–private partnerships
 - ADNI, 9, 178, 180–181, 455–462, 510
 - AMP® AD, 63, 507–508, 510–511
 - C-Path, 11, 326
 - CTTI, 268
 - DDF, 473, 524–528, 529–532
 - funding, 472–473
 - see also* European Prevention of Alzheimer's Disease (EPAD)
- publication
 - in collaborations between academia and industry, 40, 41
 - disclosure of COIs, 432
 - of trial results, 14
- randomization of trial participants, 174, 202
- randomized withdrawal design, 246
- rat models, 107
 - PET imaging, 109, 111, 112, 116
- RDKit software, 64
- recruitment coordinators, 173
- recruitment of trial participants, 249–254
 - Alzheimer's Association programs, 252, 262, 493
 - CRO input, 312
 - diversity, 17–18, 184, 209, 211–212, 250–253, 338
 - use of digital technologies, 264, 294, 297
- GAP programs, 210–212
- numbers, 301
 - global trials, 275
 - per site, 11
- outreach, 174
- registries, 174, 252, 257–264
 - EPAD, 191–192, 196–197
 - TRC-PAD program, 181, 253, 262–264
- screening, 174, 249–250, 312
 - biomarkers, 369, 379, 460–461
 - and study partners, 334–335, 337–338
- registries, 174, 252, 257–258, 264
 - Alzheimer's Prevention Registry, 259–260
 - Brain Health Registry, 258–259
 - EPAD, 191–192, 196–197
 - FTD Disorders Registry, 219
 - Healthy Brains, 253, 261
 - TRC-PAD program, 181, 253, 262–264
 - TrialMatch, 252, 262, 493
- regulatory coordinators, 173
- regulatory matters, 13–14, 319–330
 - agencies, 277–278, 320–321, 328
 - see also* European Medicines Agency (EMA); Food and Drug Administration (FDA)
 - agency/industry interactions during drug development, 13–14, 164–165, 320, 321–327
 - approved drugs, 1, 16
 - biomarkers, 327, 390–391
 - cognitive testing, 26–27, 285–286
 - and the COVID-19 pandemic, 357–358
 - digital technologies, 295–296
 - expanded access/compassionate use, 302
 - EMA, 306
 - FDA, 301–303, 305–306
 - guidance documents, 327–328
 - international harmonization, 17, 279, 320
 - marketing authorization, 327
 - statistical analysis, 245–246
- reimbursement, 166, 211
 - of study partners, 340
- remote working
 - care delivery, 350
 - during the COVID-19 pandemic, 278, 355, 356, 358
 - monitoring trial participants, 292–295, 313–314
- representation learning, 64
- repurposing of drugs, 54–59, 67, 97, 225–226, 483, 505
- Research Attitude Questionnaire (RAQ), 338
- Resilience-AD program, 508
- resveratrol, 81
- retention of trial participants, 236, 253–254, 336, 338–339
- Revised Self-Monitoring Scale (RSMS), 220
- rhesus monkeys, 79
- rho-kinase (ROCK) inhibitors, 54–55, 226
- Right-to-Try (RTT) laws (USA), 306
- risk-based data management, 238
- risk-based monitoring, 313
- risk factors for AD, 78–79
 - age, 78
 - ethnicity, 251, 400–401
 - gender, 78, 251, 401
 - genetics, 34, 82, 276, 405
 - risk-lowering mutation, 519
- risk scores, 351
- rivastigmine, 410, 413
- rodent models *see* animal models
- Rook, Jerri, 49
- royalty investments, 473–474
- rural inhabitants, 251
- salbutamol, 58
- sales representatives, 166–167
- saliva, biomarkers in, 126
- salsalate, 226
- sample sizes, 9, 151, 232, 236, 461–462
 - global recruitment, 275
- SAPHIR trial, 155–156, 423
- saracatinib, 181
- scientific liaisons (between pharma companies and physicians), 167
- screening of patients
 - for participation in trials, 174, 249–250, 312
 - biomarkers, 369, 379, 460–461
 - in primary care for early-stage AD, 344
- screening of potential drugs, 2, 7–9, 36–38
 - Cognition Therapeutics platform, 514–516
 - collaborations between academia and industry, 40–41
 - tau-directed, 35–36
- SEED small business program, 539
- semagacestat, 96, 271
- semantic memory, 282
- senescence-accelerated mouse-prone (SAMP) model, 78
- senile dementia of the Alzheimer's type, 25
- senile plaques *see* neuritic (amyloid) plaques
- sentinels in Phase 1 trials, 139, 141
- serious adverse events, 175
- severe AD, 7, 488
 - cannabinoid treatment, 186, 510
- Severe Impairment Battery (SIB), 7
- side effects *see* adverse events
- sigma-2 receptor complex, 516, 519–520
 - antagonists *see* CT1812
- simulations and model selection, 238–240
- single ascending dose (SAD) tolerance studies, 3, 138–140
- safety
 - ACTC unit, 184
 - DSMBs, 163–164, 267, 271
 - monitoring for ARIA, 5, 114, 154, 371, 379–380, 492–493
 - in Phase 1 trials, 137, 139, 141, 143–144, 146–147
 - in Phase 2 trials, 152, 154
- sirtuin, 414
- site managers, 173
- sites for clinical trials *see* trial site
- infrastructure and management
- slope effect, 239
- small business funding, 467–468, 498–499, 516, 533–541
- smartphones, 264, 294
- solanezumab, 27, 28, 179, 398
- sortilin (anti-sortilin mAb AL001), 222, 223, 537
- South Korea, 349, 350
- Souvenaid, 423–424
- SPARK program, 438–447
- spinal muscular atrophy (SMA), 370

- sponsored research agreements (SRAs), 40–41
- spouses as study partners, 337, 338
- staff
 - clinical research associates, 312–313, 316 and the COVID-19 pandemic, 355, 356, 357
 - dementia specialists, 345
 - generational shift in researchers, 501
 - investment in, 497, 499–500
 - pharmaceutical companies, 167
 - at trial sites, 11, 172–173
 - clinical raters, 173, 176, 208, 314
 - conflicts of interest, 432
 - training, 18, 184, 185, 279, 511
- stages of AD, 5–6, 233, 487–488
- staggered start design, 246
- start-up companies, 467–468, 498–499, 533–541
- statins, 128
- statistics, 232–247
 - analysis, 240–244, 271
 - ATRI/ACTC, 183–184
 - EPAD proof-of-concept platform, 202–203
 - screening assays, 36
- stem cells (iPSCs), 3, 36, 96–97, 100–104, 126–127
- stock market launch (IPO), 469–470
- storage of tissue samples, 124
- streptozotocin (STZ), 78–79
- study partners (caregivers), 333–340, 486
 - impact of COVID-19, 355
- subgroup analysis, 242
- sub-investigators (sub-I), 172
- subjective cognitive decline, 421
 - see also* mild cognitive impairment
- SV Health Investors, 525
- syndication, 527–528, 531
- t-tau *see* total tau
- tacrine, 26, 74, 411
- tarenflurbil, 28
- target engagement, 4, 158, 370, 516
- target identification, 2, 8, 45–46
 - AMP® AD, 63, 507
 - by AI, 66
 - DDF-funded, 529–530
 - upstream points, 516–517
- tau
 - animal models, 76–77, 79, 107, 109–110
 - in blood, 351, 364, 365–367, 369
 - in CSF, 116, 152, 361, 362–363
 - drugs targeting, 29, 223–226
 - EEG changes, 423
 - in FTLT, 216, 217, 219, 220–221, 223–226
 - as an outcome marker, 370
 - pathology, 27, 45, 76–77, 362–363, 365–367, 377–378
 - PET imaging, 109–110, 153, 377, 386–388, 461
 - progression of AD, 377–378
 - screening assays, 35–36
 - screening of trial participants, 152, 369
 - vaccination, 143, 225
- Tau 2020 Global Conference, 492
- Tau Consortium, 218
- Tau Pipeline Enabling Program (T-PEP), 490
- TDP pathology in FTLT, 216, 217, 222–223
- tele-care, 350
- tele-monitoring, 292–295, 313–314
- tele-working during the COVID-19 pandemic, 278, 355, 356, 358
- termination of a trial, 175
 - early, 163–164, 237, 271–272, 357–358, 434
- Tetra Therapeutics Inc., 538
- Tg2576 mouse model, 76
- Therini Bio, 529
- 3×Tg mouse model, 76–77
- tideglusib, 226
- timescale of drug development, 28
- tolerance studies, 3, 137, 138–143
- toll-like receptors (TLR3/TLR4), 77–78
- TOMM40 (mitochondrial translocase), 414
- topotecan, 67
- total tau (t-tau), 361, 362–363, 364, 366–367
- toxicity, 2–3, 73, 137
 - see also* adverse events
- training
 - academics in translational research, 438, 442, 447, 484, 499
 - clinical raters, 208, 314
 - DSMB members, 273
 - lumbar puncture technique, 312
 - physicians, 350
 - small businessmen
 - entrepreneurship, 539–540
 - grant applications, 541
 - trialists, 18, 184, 185, 279, 511
- trajectory of drug development process, 1–7, 162–163
- transcriptional profiling, 58
- transcriptomics, 129
 - PSEN1* mutants in EOAD patients, 102–104
- transgenic rodents, 3, 75–77, 83, 106–107
 - see also* animal models
- translational research, 18–19
 - Alzheimer's Association, 486–487, 489–490
 - Harrington Discovery Institute, 46–53, 483–484, 499
 - NIH–NIA funding, 503–512
 - for small businesses, 467–468, 533–541
 - TREAT-AD Center, 86–91
 - SPARK program, 438–447
 - valley of death, 9, 46, 147, 474, 480, 481, 497–499, 517–518
 - venture capital, 8–9, 469, 481, 524–532
 - venture philanthropy, 13, 473, 481–484, 497–499
- transport to/from trial sites, 209
- transporter genes, 408
 - ABCs, 412, 413
 - acetylcholine metabolism, 406
- traumatic brain injury, 180–181, 366, 401
- TREAT-AD Center (TaRget Enablement to Accelerate the Development of Therapies for AD), 86–91, 509–510
- treatment effects, 233, 238–239, 240–242, 288
 - biomarkers, 236, 370–371, 380–381, 388–389, 461
- TREM2* mutations, 82
- Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD), 181, 253, 262–264
- trial site infrastructure and management, 11–12, 170–176
 - ACTC, 182–187
 - COVID-19 and future pandemics, 315–316, 355–357
 - CRO roles and responsibilities, 172, 311–315
 - EEG, 425–426
 - EPAD TDC network, 192, 198
 - GAP-Net, 208, 209–210
 - global trials, 276, 279, 314–315
 - imaging procedures, 173, 382, 390
 - initiation, 173, 311–312
 - monitoring, 174–175, 312–314
 - selection of sites, 172, 311
 - termination, 175, 434
 - trial networks, 16, 175, 208, 209–210
- trialists, 172–173
 - conflicts of interest, 432
 - training, 18, 184, 185, 279, 511
- TrialMatch service, 252, 262, 493
- TSPO transporter protein, 389–390
- type I error (α), 37, 245
 - in cognitive testing, 287
- type II error (β), 37, 245–246
- UK
 - Dementia Discovery Fund, 473, 524–525
 - NICE, 166
 - regulatory agency (MHRA), 328
- urine, biomarkers in, 125–126
- US POINTER trial, 493
- USA
 - Cures Act, 305, 320
 - epidemiology, 31, 45, 465
 - expanded access/compassionate use, 301–308
 - government funding, 496
 - NIH, 16, 86, 452, 466–468, 480–481, 503–512
 - small business programs, 467–468, 516, 533–541
 - state level, 514–515
 - NAPA, 449, 467, 503, 513–514
 - NIH *see* National Institutes of Health
 - projected wait times, 347
 - regulatory agency *see* Food and Drug Administration (FDA)
 - reimbursement, 166, 211
- UsAgainstAlzheimer's (UsA2), 13, 207

Index

vaccination	venture philanthropy, 13, 473, 481–484, 497–499	wearable monitoring devices, 294
amyloid, 27, 75, 127–128	<i>see also</i> Alzheimer's Drug Discovery Foundation (ADDF)	western blots, 81
tau peptides, 143, 225	vesicular acetylcholine transporter (VACHT), 407	white-matter disease, 379, 382–383
valaciclovir, 56–57	Department of Veterans Affairs (VA), 268	women <i>see</i> females
valley of death in funding, 9, 46, 147, 474, 480, 481, 497–499, 517–518	video calls, 314	worldwide ADNI, 459–460
vascular disease, 508	voxel-based morphometry (VBM), 112	xamoterol, 446
venture capital, 8–9, 469, 481, 524–532	VU319, 49	Z' -value, 36